Dendritic cell-activated cytotoxic T lymphocytes cells - Shenzhen Hornetcorn Biotechnology

Alternative Names: DC activated CTL - Shenzhen Hornetcorn Biotechnology; DC-CTL - Shenzhen Hornetcorn Biotechnology; Dendritic cell cytotoxic T lymphocyte cell therapy - Shenzhen Hornetcorn Biotechnology

Latest Information Update: 20 May 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Shenzhen Hornetcorn Biotechnology
Class Antineoplastics; Cell therapies; Dendritic cell vaccines
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

06 May 2016 Shenzhen Hornetcorn Bio-technology Company plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy) in China (IV) (NCT02766348)
05 May 2016 Clinical trials in Non-small cell lung cancer in China (IV) before May 2016

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.